Labcorp Launches H5 Bird Flu Molecular Test In U.S.
(RTTNews) - Labcorp Holdings Inc. (LH), Tuesday announced the launch of H5 bird flu molecular test in the U.S., except the New York state, to detect the potential cases of bird flu in humans.
The test, which can be ordered by physicians, uses polymerase chain reaction technology and a specific reagent validated to detect the presence of the H5 virus genetic material.
The launch comes as the number of human cases with bird flu has been increasing lately, especially in U.S. dairy and poultry workers.
Currently, Labcorp's stock is trading at $229.51, down 0.05 percent on the New York Stock Exchange.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.